Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $3.01 0.5000 +19.92%
CBMG $35.64 4.5100 +14.49%
BLRX $2.02 0.1700 +9.19%
XBIT $20.59 1.5400 +8.08%
INO $8.83 0.5700 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CALA $11.00 -1.0200 -8.49%
TKAI $10.95 -0.9100 -7.67%
CLSN $2.63 -0.1701 -6.08%
CVM $0.75 -0.0400 -5.06%
BDSI $8.10 -0.3900 -4.59%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

London Hospital Pilots Apple Watch App in Chemotherapy

(Pharmafile [UK]) May 15, 2015 - King's College Hospital in London is piloting a scheme whereby cancer patients moving through chemotherapy treatments are given an Apple Watch to manage their medication.
read article 



Personalized Healthcare and Early Cancer Detection at the Heart of MIT's Research in Singapore

(Forbes) May 14, 2015 - Researchers are working on a "blood test" that could replace the more invasive biopsy, and open also the doors to personalized treatments of the disease.
read article 



FDA Grants Orphan Drug Designation to GlycoMimetics’ GMI-1271 For Treatment of Acute Myleogenous Leukemia

(MarketWatch) May 14, 2015 - GlycoMimetics, Inc. announced today that the FDA has granted Orphan Drug designation to GMI-1271, a novel and proprietary E-selectin antagonist in the company’s pipeline for treatment of patients with acute myeloid leukemia (AML).
read article 



21st Century Cures Draft Moves Forward

(ACCC) May 14, 2015 - ACCC commends the House Energy and Commerce Committee for its bipartisan effort to advance medical research and patient care through the 21st Century Cures Initiative.
read article 



Updated Breast Cancer Screening Recommendation Could Eliminate Guaranteed Coverage of Mammography for 17M Women

(Avalere) May 13, 2015 - A new analysis from Avalere finds that 17 million women ages 40 to 49 could lose their guarantee of mammogram coverage, if new breast cancer screening guidelines from the United States Preventive Services Task Force (USPSTF) are finalized.
read article 



Committee of Elite Oncologists Selects World’s Best to Receive OncLive’s 2015 Giants of Cancer Care™ Awards

(PRWeb) May 14, 2015 - Honorees will be announced Friday, May 29, during celebration in Chicago.
read press release 



Merck KGaA Reveals ASCO Plans

(Pharmafile [UK]) May 15, 2015 - Merck KGaA is the latest company to announce its slate for this year’s ASCO conference, and like other firms it will be highlighting its immuno-oncology and precision medicine candidates.
read article 



The Drugs to Watch in Fight Against Cancer

(Financial Times) May 15, 2015 - About 30,000 doctors and scientists will arrive in Chicago in two weeks for the annual meeting of the American Society of Clinical Oncology (Asco), where they will pore over data from thousands of clinical trials.
read article (free subscription required) 



Dicerna Announces Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNETs)

(MarketWatch) May 14, 2015 - Dicerna Pharmaceuticals, Inc. today announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multiple myeloma, or lymphoma to include a cohort of patients with pancreatic neuroendocrine tumors (PNETs) following early signs of clinical and metabolic response and tumor shrinkage in PNET patients.
read article 



Smoking Induces Early Signs of Cancer in Cheek Swabs

(University College London) May 14, 2015 - DNA damage caused by smoking can be detected in cheek swabs, finds research published today in JAMA Oncology. The study provides evidence that smoking induces a general cancer program that is also present in cancers which aren’t usually associated with it – including breast and gynaecological cancers.
read article 



Study: Breast Cancer Patients Need Better Cardiac Monitoring

(MedPage Today) May 13, 2015 - Breast cancer patients received suboptimal cardiac monitoring during treatment with trastuzumab (Herceptin).
read article (free registration required) 



Myriad Validates Active Surveillance Threshold with Prolaris® for Men with Prostate Cancer

(MarketWatch) May 15, 2015 - Additional data show Prolaris changed treatment plans in 48 percent of cases.
read article 



Oncotype DX(R) Prostate Cancer Test Improves Risk Assessment for One in Four Men and Reduces Overall Healthcare Cost

(Genomic Health) May 15, 2015 - Genomic Health, Inc. today announced results from three studies that show the real-world positive impact of the Oncotype DX® Genomic Prostate Score (GPS) and the test's value in managing healthcare costs associated with treatment decisions in low-risk patients.
read corporate press release 



Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015

(MarketWatch) May 13, 2015 - Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14 trial in newly diagnosed glioblastoma.
read article 



Dicerna to Present Interim Clinical Data from First DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting

(TheStreet) May 13, 2015 - Dicerna Pharmaceuticals, Inc. today announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma will be presented at ASCO.
read article 



New Data from IMAGE 1 Show Improved Survival in Metastatic Pancreatic Cancer in Patients Receiving IMM-101

(SYS-CON Media) May 14, 2015 - Immodulon Therapeutics today announced updated results of long-term survival from IMAGE 1, a randomized, controlled, open-label, Phase II clinical trial comparing the combination of IMM-101 and gemcitabine (IMM-101 treated) versus gemcitabine alone (control) as first-line treatment for advanced pancreatic cancer.
read article 



Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment

(Morningstar Advisor) May 14, 2015 - Generex Biotechnology Corporation announced today that updated data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO).
read article 



Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2015

(Celgene) May 13, 2015 - Total of eight approved therapies and investigational agents being evaluated in 15 diseases.
read corporate press release 



Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers to be Presented at 2015 ASCO Annual Meeting

(Benzinga) May 14, 2015 - Astellas today announced several abstracts across multiple cancers that will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting on May 29-June 2 in Chicago.
read article 



PharmaMar Announces New Advances in Oncology at ASCO 2015 for Its Compounds YONDELIS® and PM1183 in Small Cell Lung Cancer, Soft Tissue Sarcoma, and Mesothelioma

(PharmaMar) May 14, 2015 - PharmaMar announces that it will present several clinical studies to showcase the data obtained in various tumor types, including SCLC, soft tissue sarcoma and mesothelioma during the 51st American Society of Clinical Oncology meeting in Chicago (ASCO; May 29-June 2).
read corporate press release 



Boehringer Ingelheim Showcases Expanding Presence in Lung Cancer at ASCO 2015 with New Data Including Presentation of Afatinib Overall Survival Results for Squamous Cell Carcinoma of the Lung

(Yahoo! News) May 14, 2015 - A total of nine abstracts, including new data for afatinib and nintedanib, will emphasize the growing presence of Boehringer Ingelheim in lung and other cancer types.
read article 



Merck to Present Data at ASCO that Illustrate How the Company is Tackling Difficult-to-Treat Cancers

(Merck) May 15, 2015 - New data on priority candidates from Merck KGaA, Darmstadt, Germany's oncology and immuno-oncology pipeline are being presented, including avelumab, evofosfamide and tepotinib.
read corporate press release 



‘Safety Switch’ Kills Haywire Immune Cells in Transplant Test

(Bloomberg) May 14, 2015 - A “safety switch” drug by Bellicum Pharmaceuticals Inc. killed off overactive immune system cells in a study of transplant patients, raising hopes that the treatment can also be used to manage risks in an experimental class of cancer therapies.
read article 



Feds Say That in Screening Colonoscopies, Anesthesia Comes with No Charge

(Kaiser Health News) May 15, 2015 - Earlier this week the federal government clarified that insurers can’t charge people for anesthesia administered during a free colonoscopy to screen for colorectal cancer.
read article 



Embattled Scope Makers Won't Speak at FDA Superbug Hearing

(Los Angeles Times) May 14, 2015 - Olympus Corp. and two other manufacturers of medical scopes linked to a string of superbug outbreaks declined to speak Thursday at a Food and Drug Administration hearing on the deadly problem.
read article (free registration required)